NEW YORK, NY / ACCESSWIRE / August 24, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Zymergen Inc. (NASDAQ:ZY)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/zymergen-inc-loss-submission-form?prid=18879&wire=1
Lead Plaintiff Deadline: October 4, 2021
This lawsuit is on behalf of investors who purchased ZY common stock pursuant and/or traceable to the documents issued in connection with the Company's April 2021 initial public offering.

Allegations against ZY include that: (1) during the qualification process for the Company's optical film product, Hyaline, key customers had encountered technical issues, including product shrinkage and incompatibility with customers' processes; (2) though the qualification process was critical to achieving market acceptance for Hyaline and generating revenue, Zymergen lacked visibility into the qualification process; (3) as a result, the Company overestimated demand for its products; (4) as a result of the foregoing, the Company's product delivery timeline was reasonably likely to be delayed, which in turn would delay revenue generation; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

View, Inc. f/k/a CF Finance Acquisition Corp. II (NASDAQ:VIEW)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/view-inc-f-k-a-cf-finance-acquisition-corp-ii-loss-submission-form?prid=18879&wire=1
Lead Plaintiff Deadline: October 18, 2021
Class Period: November 30, 2020 - August 16, 2021

Allegations against VIEW include that: (1) View had not properly accrued warranty costs related to its product; (2) there was a material weakness in View's internal controls over accounting and financial reporting related to warranty accrual; (3) as a result, the Company's financial results for prior periods were misstated; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Sesen Bio, Inc. (NASDAQ:SESN)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/sesen-bio-inc-loss-submission-form?prid=18879&wire=1
Lead Plaintiff Deadline: October 18, 2021
Class Period: December 21, 2020 - August 17, 2021

Allegations against SESN include that: (1) Sesen Bio's clinical trial for its cancer treatment product, Vicineum, had more than 2,000 violations of trial protocol, including 215 classified as "major"; (2) three of Sesen Bio's clinical investigators were found guilty of "serious noncompliance," including "back-dating data"; (3) Sesen Bio had submitted the tainted data in connection with the Biologics License Application ("BLA") for Vicineum; (4) Sesen Bio's clinical trials showed that Vicineum leaked out into the body, leading to side effects including liver failure and liver toxicity, and increasing the risks for fatal, drug-induced liver injury; (5) as a result of the foregoing, the Company's BLA for Vicineum was not likely to be approved; (6) as a result of the foregoing, there was a reasonable likelihood that Sesen Bio would be required to conduct additional trials to support the efficacy and safety of Vicineum; and (7) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong